Dublin, May 30, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Hepatitis C Disease Forecast and Market Analysis to 2035" report to their offering. Hepatitis C is a blood-borne liver disease caused by the hepatitis C virus (HCV). HCV belongs to the Flaviviridae virus family and is a communicable disease spread primarily through direct contact with the blood or the bodily fluids of an infected individual, including sexual and mother-to-child transmission. Hepatitis C infection normally does not produce signs or symptoms and, as such, most people who are infected do not know they have the disease. Approximately 15% of infected individuals are able to clear the virus and are free from associated complications. The remaining 85% of individuals are at risk of chronic hepatitis and complications associated with chronic infection, such as scarring, liver cancer, and liver failure. An estimated 20-30% of chronic HCV patients go on to develop cirrhosis, while 1-5% will develop liver cancer. Key Topics Covered: 1. FORECAST: HEPATITIS C Executive Summary Market Overview and Trends Market Definition and Methodology Daklinza (daclatasvir) glecaprevir/pibrentasvir Harvoni (sofosbuvir/ledipasvir) Olysio (simeprevir) sofosbuvir/velpatasvir sofosbuvir/velpatasvir/GS-9857 Sovaldi (sofosbuvir) Sunvepra (asunaprevir) Technivie (paritaprevir/ritonavir/ombitasvir) Viekira Pak (paritaprevir/ritonavir/ombitasvir + dasabuvir) Zepatier (grazoprevir/elbasvir) Primary Research Methodology 2. TREATMENT: HEPATITIS C Executive Summary Primary Research Methodology Disease Definition and Diagnosis Patient Segmentation Current Treatment Options Country Treatment Trees Prescribing Trends Unmet Needs in Hepatitis C 3. EPIDEMIOLOGY: HEPATITIS C IN THE US, JAPAN, AND 5EU Executive Summary Disease Overview Sources and Methodology Forecast Epidemiologist Insight Strengths and Limitations Appendix 4. MARKETED DRUGS: HEPATITIS C Executive Summary Product Overview Product profile: Daklinza Product profile: Epclusa Product profile: Harvoni Product profile: Olysio Product profile: Sovaldi Product profile: Sunvepra Product profile: Viekira Pak Product profile: Zepatier 5. HEPATITIS C PRICING AND REIMBURSEMENT Executive Summary Market Context US Japan Five Major EU Markets 6. PIPELINE: HEPATITIS C Executive Summary Clinical Pipeline Overview Early-Phase Opportunities Product profile (late stage): DCV-TRIO Product profile (late stage): glecaprevir/pibrentasvir Product profile (late stage): sofosbuvir/velpatasvir/voxilaprevir For more information about this report visit http://www.researchandmarkets.com/research/tz...epatitis_c
CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Related Topics: Infectious Diseases Drugs, Liver and Kidney Disorders Drugs